AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (active enrollment and teaching how to use the EPP)
Number of subjects: 229
Study 35969452 — intervention group
Group type: COMPARATOR
Intervention: Control group (information on how to enroll in EPP in discharge paperwork)
Number of subjects: 229
Study 35969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (EPP use)
Number of subjects: 229
Study 35969452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (EPP use and follow-up)
Number of subjects: 229
Study 35969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by adjuvant nivolumab 480 mg once every four weeks (nine injections)
Number of subjects: 32
Study 35969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab and ipilimumab
Number of subjects: 32
Study 35969830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 32
Study 35970164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation (CI)
Number of subjects: 97
Study 35970164 — intervention group
Group type: COMPARATOR
Intervention: Control (no cochlear implant)
Number of subjects: 97
Study 35970439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 35970439 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 35970714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP (60 mg/kg) weekly for 52 weeks
Number of subjects: 0
Study 35970920 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab
Number of subjects: 0
Study 35970920 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study 35970951 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP) lead connected to a dual-chamber DF-1 ICD
Number of subjects: 10
Study 35970951 — intervention group
Group type: COMPARATOR
Intervention: Conventional RV sensing configuration
Number of subjects: 10
Study 35971017 — intervention group
Group type: EXPERIMENTAL
Intervention: 1565-nm non-ablative fractional laser (NAFL)
Number of subjects: 18
Study 35971017 — intervention group
Group type: COMPARATOR
Intervention: long-pulsed 1064-nm Nd:YAG laser (LPNY)
Number of subjects: 18
Study 35971031 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for myocardial blood flow (MBF) quantification
Number of subjects: 154
Study 35971031 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for myocardial flow reserve (MFR) quantification
Number of subjects: 154
Study 35971031 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for stress MBF
Number of subjects: 154
Study 35971031 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for MFR
Number of subjects: 154
Study 35971031 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT
Number of subjects: 154
Study 35971031 — intervention group
Group type: COMPARATOR
Intervention: MPI (myocardial perfusion imaging)
Number of subjects: 154
Study 35971064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided esophageal compression during pressure-controlled face-mask ventilation
Number of subjects: 42
Study 35971064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided esophageal compression
Number of subjects: 42
Study 35971072 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBP™ (smartphone application)
Number of subjects: 30
Study 35971173 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients undergoing primary PCI
Number of subjects: 15686
Study 35971173 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD patients undergoing primary PCI
Number of subjects: 15686
Study 35971243 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective surgery (O)
Number of subjects: 27
Study 35971243 — intervention group
Group type: COMPARATOR
Intervention: No corrective surgery (NO)
Number of subjects: 27
Study 35971307 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored rehabilitation program for 8 weeks
Number of subjects: 37
Study 35971307 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment during modified tilt-test
Number of subjects: 37
Study 35971307 — intervention group
Group type: COMPARATOR
Intervention: Second assessment during modified tilt-test after rehabilitation
Number of subjects: 37
Study 35971416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 231
Study 35971681 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated insulin delivery (AID) using interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours.
Number of subjects: 20
Study 35971681 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated insulin delivery (AID)
Number of subjects: 20
Study 35971857 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix administration
Number of subjects: 29
Study 35971900 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in 2017
Number of subjects: 19875
Study 35971900 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in 2019
Number of subjects: 19875
Study 35971900 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in all age groups in 2017
Number of subjects: 19875
Study 35971951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen (75-450 mg single dose; 150-450 mg multiple doses on days 1, 4, 8, 11, 15, and 22)
Number of subjects: 96
Study 35972222 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated time in range (eTIR) adjusted for HbA1c and covariates
Number of subjects: 0
Study 35972222 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) attributes at CCTA defined high disease burden (plaque burden, ≥70%; minimum lumen area, <4 mm²)
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting distal coronary artery pressure (Pd)-to-aortic pressure (Pa) ratio (Pd/Pa)
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic flow (1/hyperemic mean transit time [Tmn])
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting flow (1/resting Tmn)
Number of subjects: 0
Study 35972355 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance (IMR)
Number of subjects: 0
Study 35972454 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived stress (>50th percentile) during peri-implantation or early pregnancy
Number of subjects: 797
Study 35972454 — intervention group
Group type: COMPARATOR
Intervention: Low perceived stress (≤50th percentile) during peri-implantation or early pregnancy
Number of subjects: 797
Study 35972459 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary PVD
Number of subjects: 208
Study 35972459 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PVD
Number of subjects: 208
Study 35972667 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin/mitomycin C
Number of subjects: 18
Study 35972667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction and HIPEC
Number of subjects: 18
Study 35972787 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention including a health literacy (HL) module and 3 obesity prevention modules
Number of subjects: 0
Study 35972787 — intervention group
Group type: COMPARATOR
Intervention: Web-based intervention including a vaping module and 3 obesity prevention modules
Number of subjects: 0
Study 35972987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Galectin-3 Inhibitor
Number of subjects: 0
Study 35972987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35973031 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin, dosage and duration not available
Number of subjects: 0
Study 35973148 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-hour wireless pH monitoring off PPI
Number of subjects: 132
Study 35973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of anti-HEV IgG
Number of subjects: 2012
Study 35973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for anti-HEV IgM and HEV RNA
Number of subjects: 2012
Study 35973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of acute hepatitis E
Number of subjects: 2012
Study 35973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of anti-HEV
Number of subjects: 2012
Study 35973149 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HEV infection in suspected DILI cases
Number of subjects: 2012
Study 35973168 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVE score
Number of subjects: 197
Study 35973190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab (biweekly administration for a median of 20.5 weeks)
Number of subjects: 12
Study 35973190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab (retreatment for a median of 113 weeks)
Number of subjects: 12
Study 35973190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 12
Study 35973192 — intervention group
Group type: EXPERIMENTAL
Intervention: tisagenlecleucel (tisa-cel)
Number of subjects: 285
Study 35973192 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 285
Study 35973199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enasidenib with azacitidine
Number of subjects: 50
Study 35973199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy after prior hypomethylating agent (HMA) therapy
Number of subjects: 50
Study 35973200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for up to 2 years)
Number of subjects: 12
Study 35973665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision.
Number of subjects: 281
Study 35973700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled admissions (PCA)
Number of subjects: 45
Study 35973737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg IV every 3 weeks for 4 cycles, then 1000 mg IV every 6 weeks)
Number of subjects: 88
Study 35973801 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in obese patients (BMI ≥ 30) during pregnancy
Number of subjects: 55
Study 35973801 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP levels in nonobese patients (BMI < 30) during pregnancy
Number of subjects: 55
Study 35973801 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in obese patients (BMI ≥ 30) postpartum (up to 4 to 6 weeks)
Number of subjects: 55
Study 35973801 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP levels in nonobese patients (BMI < 30) postpartum (up to 4 to 6 weeks)
Number of subjects: 55
Study 35973801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive disorders of pregnancy in obese patients (BMI ≥ 30)
Number of subjects: 55
Study 35973801 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive disorders of pregnancy in nonobese patients (BMI < 30)
Number of subjects: 55
Study 35973887 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-extended FFQ
Number of subjects: 100
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-21
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating R-CHOP-21 and modified R-DHAOx
Number of subjects: 60
Study 35974101 — intervention group
Group type: COMPARATOR
Intervention: Historical comparator (CHOP)
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year time to progression
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year overall survival (OS)
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year OS in low-risk group
Number of subjects: 60
Study 35974101 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related mortality
Number of subjects: 60
Study 35974168 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib combined with endocrine therapy (ET)
Number of subjects: 0
Study 35974168 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) only
Number of subjects: 0
Study 35974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Early menopause (40-44 years)
Number of subjects: 18326
Study 35974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight loss since age 20
Number of subjects: 18326
Study 35974320 — intervention group
Group type: COMPARATOR
Intervention: Daily alcohol consumption in the third quartile (5.36-11.42 g/day)
Number of subjects: 18326
Study 35974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age and weight at baseline, current smoking, positive history of previous fracture, family history of fractures
Number of subjects: 18326
Study 35974320 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 18326
Study 35974328 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Healing and Seeking Safety (IHSS)
Number of subjects: 402
Study 35974328 — intervention group
Group type: COMPARATOR
Intervention: No IHSS
Number of subjects: 402
Study 35974328 — intervention group
Group type: EXPERIMENTAL
Intervention: IHSS
Number of subjects: 402
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological surgery (benign conditions)
Number of subjects: 271
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological surgery (malignant conditions)
Number of subjects: 271
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 271
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation for low resilience
Number of subjects: 271
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and life satisfaction measures
Number of subjects: 271
Study 35974326 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression measures
Number of subjects: 271
Study 35974422 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 118
Study 35974874 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural procreative technology treatment
Number of subjects: 834
Study 35974896 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies testing
Number of subjects: 682
Study 35974896 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention measures (proper use of alcohol-based hand rub, soap and water, wearing PPE)
Number of subjects: 682
Study 35975199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplexed, baited, targeted proteomics assay for detection of SARS-CoV-2 anti-spike antibody immunocomplex
Number of subjects: 0
Study 35975199 — intervention group
Group type: COMPARATOR
Intervention: Standard ELISA-based serology
Number of subjects: 0
Study 35975210 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 35975210 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 35975210 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RAs
Number of subjects: 0
Study 35975738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with ifosfamide-carboplatin-etoposide (BV-ICE)
Number of subjects: 52
Study 35976085 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 353512 targeting human C-reactive protein (CRP)
Number of subjects: 0
Study 35976085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine pretreatment of PBMCs
Number of subjects: 0
Study 35976085 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminator donor PBMCs
Number of subjects: 0
Study 35976085 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC assay using discriminator donors
Number of subjects: 0
Study 35976085 — intervention group
Group type: COMPARATOR
Intervention: Known benchmark ASO controls
Number of subjects: 0
Study 35976192 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of virtual reality tele-exergaming intervention
Number of subjects: 34
Study 35976192 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 34
Study 35976232 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vascular bed area (RVBA) in eyes with RVO
Number of subjects: 30
Study 35976232 — intervention group
Group type: COMPARATOR
Intervention: Retinal vascular bed area (RVBA)
Number of subjects: 30
Study 35976252 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 42
Study 35976252 — intervention group
Group type: COMPARATOR
Intervention: ILM nonpeeling
Number of subjects: 42
Study 35976282 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn Disease Exclusion Diet (CDED)
Number of subjects: 18
Study 35976282 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 18
Study 35976282 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline microbiome analysis
Number of subjects: 18
Study 35976415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 71
Study 35976570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 241
Study 35976570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 241
Study 35976570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib (10 mg and 25 mg)
Number of subjects: 241
Study 35976570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 241
Study 35976603 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone monotherapy (2.5 or 5 mg/day)
Number of subjects: 25
Study 35977080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 251
Study 35977104 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended match time (90 + 30 min)
Number of subjects: 20
Study 35977103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with vigorous-intensity physical activity
Number of subjects: 217
Study 35977103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with sleep
Number of subjects: 217
Study 35977103 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with moderate- to vigorous-intensity physical activity
Number of subjects: 217
Study 35977357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 35977366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodless care
Number of subjects: 1111
Study 35977366 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1111
Study 35977366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodless care (medical subgroup)
Number of subjects: 1111
Study 35977366 — intervention group
Group type: COMPARATOR
Intervention: Standard care (medical subgroup)
Number of subjects: 1111
Study 35977396 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage mother's milk intake during hospitalization
Number of subjects: 143
Study 35977396 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAm at several top identified CpGs from the EWAS
Number of subjects: 143
Study 35977532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 20 mg/kg/day with dose escalation to maximum tolerated dose (MTD)
Number of subjects: 202
Study 35977532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 202
Study 35977756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus rucaparib (nivolumab 480 mg every 4 weeks plus rucaparib 600 mg two times per day)
Number of subjects: 0
Study 35977762 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting (LA) injectable PrEP
Number of subjects: 293
Study 35977762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pills
Number of subjects: 293
Study 35977762 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (general)
Number of subjects: 293
Study 35977832 — intervention group
Group type: EXPERIMENTAL
Intervention: PWWE
Number of subjects: 331
Study 35977832 — intervention group
Group type: COMPARATOR
Intervention: HPW
Number of subjects: 331
Study 35977832 — intervention group
Group type: COMPARATOR
Intervention: NPWWE
Number of subjects: 331
Study 35977881 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 707
Study 35977881 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 707
Study 35977936 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV111 (neoadjuvant treatment)
Number of subjects: 0
Study 35978373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 411
Study 35978394 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tAN
Number of subjects: 31
Study 35978394 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tAN (Group 1)
Number of subjects: 31
Study 35978394 — intervention group
Group type: COMPARATOR
Intervention: Sham tAN (Group 2)
Number of subjects: 31
Study 35978394 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tAN (Days 2-5)
Number of subjects: 31
Study 35978403 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 3000
Study 35978403 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest value of two FIT at cutoff 10 μg Hb/g faeces
Number of subjects: 3000
Study 35978403 — intervention group
Group type: COMPARATOR
Intervention: Reference test linked to the Swedish Colorectal Cancer Registry
Number of subjects: 3000